Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Pediatric blood & cancer - 1 Jun 2014

Shaw Kaitlyn, Amstutz Ursula, Hildebrand Claudette, Rassekh S Rod, Hosking Martin, Neville Kathleen, Leeder J Steven, Hayden Michael R, Ross Colin J, Carleton Bruce C

Abstract excerpt

BACKGROUND: Despite substantial evidence supporting a pharmacogenetic approach to warfarin therapy in adults, evidence on the importance of genetics in warfarin therapy in children is limited, particularly for clinical outcomes. We assessed the contribution of CYP2C9/VKORC1/CYP4F2 genotypes and variation in other genes involved in vitamin K and coagulation pathways to warfarin dose and related clinical outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cardiac Surgical Procedures

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P450 Family 4

Share to Hemorrhage

Share to International Normalized Ratio

Share to Postoperative Complications

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 24474498
DOI: 10.1002/pbc.24932

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.PMID 24474498Read ↗

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.Semantic proximity Read ↗

Characterizing variability in warfarin dose requirements in children using modelling and simulation.Semantic proximity Read ↗

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.Semantic proximity Read ↗

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.Semantic proximity Read ↗

The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Semantic proximity Read ↗

Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Semantic proximity Read ↗

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.Semantic proximity Read ↗

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.Semantic proximity Read ↗

Genetic and clinical determinants influencing warfarin dosing in children with heart disease.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.